Nanocoating Shows Promise in Protecting Transplanted Islets from Immune Rejection

Pancreatic islet transplantation offers potential for people with Type 1 diabetes to restore their own insulin production. However, the immune system recognizes transplanted islets as foreign and attacks them, leading to rejection and loss of function. To make transplantation more viable, researchers need strategies to protect the islets from immune attack while keeping them functional.

Researchers developed a novel approach: coating islet cells with an ultra-thin multilayered nanocoating made from two materials—tetrahydropyran triazole phenyl-alginate and quaternized phosphocholine-chitosan. These polyelectrolytes are designed to be non-immunogenic, meaning they should not trigger an immune response themselves. The coating is applied using a layer-by-layer assembly process that creates a conformal coating closely matched to the islet's surface.

In laboratory experiments, the researchers studied how the coating affects immune cells. When the coated islets were exposed to antigen-presenting cells (APCs)—immune cells that initiate rejection—the coating appeared to reduce the activation and maturation of these cells. This suggests the coating may help quiet the immune response against the transplanted tissue.

The coated islets were transplanted into mice with diabetes induced by streptozotocin (STZ), which damages the pancreas and mimics Type 1 diabetes. The transplanted, coated islets successfully restored normal blood sugar levels in these mice. The researchers confirmed the results using multiple measurements: blood glucose tests, glucose tolerance tests, and examination of the transplanted tissue under the microscope.

These findings suggest that a protective nanocoating strategy may help islet transplants survive longer and function better by modulating immune rejection. The approach was tested in syngeneic transplants (using genetically identical mice), which represent an idealized transplant scenario. Human transplantation involves additional immune complexity and differences between donor and recipient. Further research will be needed to determine whether this technology can translate to clinical use in people with Type 1 diabetes.

Source: Bioengineering & translational medicine. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.